Clinical Trials
40 trialsNCT07252739 2026-05-26
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07024784 2026-05-19
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06623656 2026-04-21
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT07274384 2025-12-10
HYPERBOLIC
Università Vita-Salute San Raffaele
Phase 2 Not yet recruiting
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT05456685 2025-10-28
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
Phase 2 Active not recruiting
NCT01295944 2025-08-05
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06942416 2025-04-24
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT05964101 2024-05-21
GALAXY-1
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT03935256 2023-12-18
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
Phase 2 Unknown
NCT01616303 2020-09-14
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
Phase 2 Completed
NCT02259582 2020-09-09
DENALI
Mereo BioPharma
Phase 2 Completed
NCT01439568 2019-07-23
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01523678 2019-07-10
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Belgian Gynaecological Oncology Group
Phase 2 Completed
NCT02592876 2019-05-17
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT00870870 2018-06-01
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Eli Lilly and Company
Phase 2 Completed
NCT00408070 2018-03-08
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
UConn Health
Phase 2 Terminated
NCT00480831 2017-05-18
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Genentech, Inc.
Phase 2 Completed
NCT01075100 2016-12-07
Ixabepilone + Carboplatin Metastatic Breast Cancer
US Oncology Research
Phase 2 Completed
NCT00129727 2016-06-01
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Massachusetts General Hospital
Phase 2 Completed
NCT00588666 2016-01-22
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00588094 2015-12-04
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00758732 2015-09-28
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00653939 2015-02-09
FALCON
Mateon Therapeutics
Phase 2 Completed
NCT01127763 2014-04-09
RAD001 Plus Carboplatin in Breast Cancer Patients
NYU Langone Health
Phase 2 Completed
NCT00247416 2014-03-07
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
University of Kentucky
Phase 2 Completed
NCT00413283 2013-10-24
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed
NCT00660140 2013-08-13
Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00610714 2012-12-18
OVERT-1
AstraZeneca
Phase 2 Completed
NCT00929162 2012-08-07
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
AstraZeneca
Phase 2 Terminated
NCT00561795 2012-03-22
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Phase 2 Completed
NCT00453635 2012-03-13
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00113438 2011-11-01
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
Mateon Therapeutics
Phase 2 Completed
NCT00057473 2011-04-14
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
Bristol-Myers Squibb
Phase 2 Completed
NCT00135135 2008-06-03
Therapy for Children With Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00034346 2007-12-24
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed